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ABSTRACT  
 
Invasive breast cancer is the most common malignancy in women. Its most common 
site of metastasis is represented by the lymph nodes of axilla, and the sentinel lymph 
node (SLN) is the first station of nodal metastasis. Axillary SLN biopsy accurately 
predicts axillary lymph node status and has been accepted as standard of care for 
nodal staging in breast cancer. To date, the morphologic aspects of SLN metastasis 
have not been considered by the oncologic staging system. Extranodal extension 
(ENE) of nodal metastasis, defined as extension of neoplastic cells through the nodal 
capsule into the peri-nodal adipose tissue, has recently emerged as an important 
prognostic factor in several types of malignancies. It has also been considered as a 
possible predictor of non-sentinel node tumor burden in SLN-positive breast cancer 
patients. We sought out to clarify the prognostic role of ENE in SLN-positive breast 
cancer patients in terms of overall and disease-free survival by conducting a 
systematic review and meta-analysis. Among 172 screened articles, 5 were eligible 
for the meta-analysis; they globally include 624 patients (163 ENE+ and 461 ENE-) 
with a median follow-up of 58 months. ENE was associated with a higher risk of both 
mortality (RR= 2.51; 95% CI: 1.66-3.79, p<0.0001, I2=0%) and recurrence of disease 
(RR=2.07, 95%CI: 1.38-3.10, p<0.0001, I2=0%). These findings recommend the 
consideration of ENE from the gross sampling to the histopathological evaluation, in 
perspectives to be validated and included in the oncologic staging. 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
4 
 
 
INTRODUCTION 
 
Invasive breast cancer is the most common malignancy in women, representing 23% 
of all cancers in woman globally and 27% in affluent countries. It is more than twice 
as common as cancer at any other site [1]. The most common site of metastasis of 
breast cancer is represented by the lymph nodes of axilla, and the sentinel lymph node 
(SLN) is the first station of nodal metastasis [1-3].  
Axillary SLN biopsy was introduced in the management of patients affected by T1 
and T2 breast cancer and has become the standard care for these patients, being an 
accurate method in predicting other axillary lymph nodes status [2-3]. The probability 
of non-SLN metastases in patients with SLN free of metastases is less than 5%. For 
this reason, such patients can safely avoid axillary lymph node dissection and the 
associated morbidity [2-6]. Patients with positive SLN were traditionally treated with 
axillary lymph node dissection [5-6]. However, about 40-60% of these patients have 
no other metastatic axillary lymph nodes, suggesting that even this group is 
heterogeneous.  
Several factors have been studied as potential predictors of the status of axillary 
lymph nodes in patients with positive SLN, and some of them have not demonstrated 
a prognostic value. For example, the presence of isolated tumor cells in the SLN does 
not adversely impact disease free- and overall-survival, and, according to the Tumor, 
Nodes, Metastasis (TNM) staging system, isolated tumor cells are designated and 
treated as pN0(i+) [7]. At the same time, extranodal extension (ENE) has recently 
emerged as an important prognostic factor in several types of malignancies [8-11]. It 
is the extension of neoplastic cells through the nodal capsule into the peri-nodal 
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adipose tissue (Figure 1). In positive SLN, ENE has been indicated as a possible 
predictor of non-SLN tumor burden in breast cancer, but it is yet unclear if ENE in 
SLN has a significant prognostic impact [12]. 
In order to study in depth the prognostic role of ENE in positive SLN of breast cancer 
patients, we conducted a systematic review and meta-analysis of all the studies that 
have investigated the most important prognostic indicators, including overall survival 
(OS), disease-free survival (DFS) and cancer-specific survival, in patients with 
(ENE+) versus without (ENE-) ENE in SLN. 
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MATERIALS AND METHODS 
 
This systematic review adhered to the MOOSE guidelines [13] and PRISMA 
statement [14], following a predetermined but unpublished protocol.   
  
Inclusion and exclusion criteria 
Studies were considered eligible for inclusion if they satisfy the following criteria: 1) 
diagnosis of breast cancer, 2) prospective, observational cohort studies, 3) contained a 
comparison of prognostic factors between ENE+ vs. ENE- for SLN, 4) contained data 
about mortality or recurrence of disease, 5) were published in a peer review journal or 
published abstract. Exclusion criteria were: 1) no presence of cancer, 2) no data about 
prognostic parameters in the title/abstract, 3) comparison between ENE+ vs. no lymph 
nodes metastases (N0), 4) diagnosis of non-epithelial malignancies (i.e.: lymphomas), 
5) ENE+ for lymph nodes other than SLN, and 6) in vitro or animal studies. We 
considered articles written in any language.  
 
Data sources and literature search strategy 
Two investigators (C.L., N.V.) independently searched PubMed and SCOPUS until 
09/30/2015. The search terms used in PubMed included combinations of the 
following keywords: (extracapsular OR pericapsular OR extranodal OR perilymphatic 
OR perinodal OR “extra capsular” OR “peri-capsular” OR “extra nodal” OR “peri 
lymphatic” OR “peri nodal” OR “extra-capsular” OR “peri-capsular” OR “extra-
nodal” OR “peri-lymphatic” OR “peri-nodal”) AND (sentinel) AND (mortality OR 
mortalities OR fatality OR fatalities OR death* OR survival OR recurrence OR 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
7 
 
prognosis OR "hazard ratio" OR HR OR "relative risk" OR RR OR prognosis OR 
progression). A similar search was conducted in SCOPUS. We considered also the 
reference lists of all included articles. 
 
Study selection  
Following the searches as outlined above, after removal of duplicates, two reviewers 
(A.N.. and M.S.) screened independently titles and abstracts of all potentially eligible 
articles. The two authors applied the criteria of eligibility, considered the full texts 
and a final list of included articles was reached through consensus with a third 
independent author (N.V.).  
 
Data extraction  
Two authors were involved in the data extraction from a predetermined Excel 
database.  Particularly, one author (A.N.) extracted data from the included articles and 
a second independent author (C.L.) validated the data. For each article, we extracted 
information about authors, year of publication, country, exclusion criteria, tumor size 
and grading, age, ENE definition, and duration of mean follow-up. In case of missing 
data, authors were contacted at least 4 times in one month by e-mail. 
 
Outcomes 
The main outcomes were number of deaths independent from all the causes (all-cause 
mortality), number of deaths due to cancer (cancer-specific mortality), and number of 
recurrences (disease free survival) during follow-up period by ENE status. 
 
Assessment of study quality  
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The Newcastle-Ottawa Scale (NOS) [15] was used to evaluate study quality. The 
NOS provides an assessment of the methodological quality of non-randomized trials 
and its content validity and reliability have already been established [13]. Included 
studies are judged on 8 items across three key areas: selection of the participants, 
comparability of the participants, and outcomes. One author (C.L.) completed the 
NOS and each study receives an overall score for methodological quality of up to 9 
points.  
 
Data synthesis and statistical analysis  
All analyses were conducted using Comprehensive Meta-Analysis (CMA) 3.  
In our primary analyses, pooled risk ratios (RRs) and 95% CIs of all-cause mortality 
and recurrences of disease between ENE+ vs. ENE- were calculated using 
DerSimonian-Laird random-effects models [16]. Since data about hazard ratios (HRs) 
adjusted for the maximum number of covariates were available only for two studies, 
we summarized these findings descriptively.   
Heterogeneity across studies was assessed by the I2 metric and chi square statistics 
[17]. Since no outcome from the meta-analysis was heterogeneous, (i.e. I2>50% 
and/or a p-value <0.05 [15]), no meta-regression analysis was performed.  
Finally, we investigated publication bias for our primary meta-analysis with a visual 
inspection of funnel plots and with the Begg-Mazumdar Kendall's tau [18] and Egger 
bias test [19].  
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RESULTS 
 
Search Results 
Altogether, 172 non-duplicated articles were identified through the literature search. 
After excluding 160 articles based on title/abstract review, 12 articles were retrieved 
for full text review and, following the application of the inclusion criteria (exclusion 
of 7 studies: doubled cohort = 1 study, no data on SLN = 3 studies, reviews = 2 
studies, no control group = 1 study), 5 unique articles resulted as eligible for this 
meta-analysis [20-24] (Supplementary Figure 1).  
 
Study and Patient Characteristics 
The studies were conducted in Europe (2 studies) [21,24], Asia (2 studies) [22,23] and 
North America (1 study) [20]. Altogether, 624 patients (163 ENE+ and 461 ENE-) 
were followed-up for a median of 58 months (range: 20-73). The median NOS score 
was 6 points (range: 5-9) (Supplementary Tables 1-2).  
All studies (except one) defined EN  using a classical definition, i.e. as the presence 
of full-thickness lymph node capsular invasion or with the extension of tumor cells 
into peri-nodal adipose tissue. Only one study [23] reported salient demographic data 
by ENE status limiting the applicability to these findings to other studies.  
 
Risk Ratios on Overall survival and Disease-Free Survival 
Pooling data from 4 studies reporting data on overall survival [20,21,23,24], 22.5% 
with ENE+ for sentinel lymph node were dead vs. 9.6% with ENE-, leading to a 
significant increased risk of mortality (RR= 2.51; 95% CI: 1.66-3.79, p<0.0001, 
I2=0%) (Table 1; Figure 2A). ENE+ was further associated to a significant higher 
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risk of recurrence of disease (5 studies) [20-24]; RR=2.07, 95%CI: 1.38-3.10, 
p<0.0001, I2=0%) (Table 1; Figure 2B).  
For both outcomes, publication bias was unlikely as indicated by the Egger’s test 
(bias=1.47; p=0.33) and Begg–Mazumdar test (Kendall’s tau = 0.17, p =0.73).  
No studies reported data on cancer-specific mortality. 
 
Descriptive findings  
Two studies [20,23] also reported results of analyses regarding the association 
between ENE and prognostic factors by ENE status, adjusted for potential 
confounders (Supplementary Table 3). Regarding OS, taking in account 5 possible 
confounders, Choi et al. [20] reported an increased risk of mortality for those having 
ENE+ at the baseline (OR=8.16, 95%CI: 1.72-38.67), while Shigematsu et al. [23] 
reported a HR of 3.70 (95%CI: 1.08-12.72) considering 9 possible confounders. 
Similar findings emerged for DFS, since Choi et al. [20] reported an OR of 5.48 
(95%CI: 1.23-24.45, p=0.03) for those ENE+ and Shigematsu et al. [23] a HR of 4.50 
(95%CI: 1.77-11.47). Due to intrinsic diversities in such indexes (OR is not 
comparable to HR), a meta-analysis summarizing them was not possible. 
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DISCUSSION 
 
In this study we analyzed 5 observational studies involving 624 SLN positive breast 
cancer patients. Of them, 163 presented extra-nodal extension, while 461 showed only 
intra-nodal metastasis. Our findings demonstrate that ENE was associated with a 
higher risk of mortality (RR= 2.51; 95% CI: 1.66-3.79, p<0.0001, I2=0%) and 
recurrence of disease (RR=2.07, 95%CI: 1.38-3.10, p<0.0001, I2=0%).  Both of the 
analyses were homogenous and without any evidence of publication bias. 
Previous studies have clearly demonstrated that ENE in axillary SLN metastasis is an 
important predictor of non-sentinel lymph node tumor burden. Cserni in 2001 and 
Stitzenberg et al. in 2003 found that ENE of the SLN metastasis is a strong predictor 
of non-SLN involvement also in multivariate analysis, and that in such cases 
completion of axillary lymph nodes dissection may be important [25,26]. These 
results were further corroborated with a meta-analysis by van la Parra et al. [12]. In 
this meta-analysis 8 factors including ENE in the SLN were identified as predictive of 
non-SLN tumor burden. With the size of SLN metastasis (>2 mm vs. ≤2 mm), ENE 
emerged as one of the most clinically relevant indexes to predict further non-SLN 
metastasis [12]. Despite a well-defined role of ENE in the SLN metastasis in the 
prediction of non-SLN involvement, its role as a prognostic factor in terms of overall 
mortality has not been established until now. Our findings show that the presence of 
ENE in SLN is strongly associated with a poor prognosis in terms of overall survival 
and disease free survival. Although there were not a sufficient number of studies 
reporting the HR, adjusted for potential confounders, to perform a meta-analysis, the 
present findings based on RR appear sufficiently robust to generate the hypothesis of 
a significant prognostic role of ENE in SLN positive breast cancer. 
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There are some important implications that can be derived from this study. The first 
regards the need of a standard definition of ENE, since this parameter, should be 
considered by future staging systems and also be reported in the final pathology 
report. Four out of 5 studies assessed ENE classically, i.e. as the extension of 
metastatic cells through the nodal capsule into the perinodal adipose tissue 
[20,21,23,24]. The study by Fujii et al. [22] considered ENE as the extra-capsular 
growth of tumor cells, the invasion of perinodal fat or the extranodal location of 
tumor cells, extending in this way the classic definition. Using this definition, also 
free tumor deposits in the adipose tissue surrounding the SLN could be included in 
our meta-analysis, introducing a possible bias. However, this study represents a minor 
proportion (7.4%) of the total number of ENE+ patients to significantly affect our 
findings, and as discussed before no heterogeneity was present. 
This point further reiterates the importance of adopting a standard definition of ENE. 
We suggest define as true ENE the one that is demonstrated histologically and 
characterized by a structural rupture of the lymph node capsule by the metastasis. 
Neoplastic emboli as well as free tumor cell deposits in adipose tissue and metastasis 
in the marginal sinus should not be considered as true ENE. Notably, the presence of 
tumor cells in the adipose tissue is recognized as associated to a poor prognosis in 
colorectal cancer. In this type of cancer, this parameter has been recognized by the 
TNM staging system designing for it a specific subcategory of N group, named N1c 
[7,9]. Furthermore, ENE has also been taken into account in the last staging systems 
of squamous cell carcinoma of the vulva, playing an important, adverse prognostic 
role [11]. In the 5th edition of the American Joint Committee on Cancer (AJCC) 
Cancer Staging Manual, ENE was considered also for breast cancer, in a specific 
subcategory, named pN1biii, but this was removed from the 6th edition of the same 
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staging system [27,28]. It is possible that some evidences against its usefulness in the 
staging system and also problems in the standardization of ENE definition, with a 
difficult inter-observer agreement, affected the consideration of its prognostic 
importance. However, on the basis of the present results, we suggest to reconsider the 
possible prognostic role of ENE, also in perspectives to be validated by future clinical 
trials. 
Recently, the Z0011 trial demonstrated no difference in loco-regional recurrence and 
overall survival in breast cancer patients with a positive SLN randomized to axillary 
lymph node dissection or no further surgery, changing the surgical management of T1 
and T2 breast cancer patients with metastatic involvement of the axilla limited to the 
SLN [29]. However, it is important recognizing patients who meet the Z0011 strict 
criteria of inclusion but at the same time have a certain high-risk characteristics, as for 
example the presence of ENE. The incidence of ENE in SLN ranges from 24% to 
40% [20,26,30]. Due to its high incidence, due to its association with non-SLN 
metastasis, as even highlighted by Cserni and Stitzenberg et al. in a multivariate 
analysis [25,26], and by van la Parra et al. in a meta-analsysis [12], and also due to the 
results of this meta-analysis, it seems advisable to offer completion of the axillary 
lymph node dissection, rather than not.   
When considering the therapeutic in other cancer types (e.g. pancreatic ductal 
adenocarcinoma), ENE+ patients seem to benefit from adjuvant chemo-radiation, but 
not from chemotherapy alone [8,31]. This aspect should be further addressed by 
future studies, and could address peculiar therapeutic approaches if confirmed also for 
breast cancers as well. Noticeably, even after the Z0011 trial, some radiation 
oncologists still recommend additional radiation fields in selected cases such as ENE+ 
in SLN [20,32]. 
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Whilst the results of this meta-analysis are clear and reliable, we have also to consider 
some limitations of our paper. The first is the small number of studies; however, the 
significant number of patients presented in these studies (mean number: 125 
patients/study) as well as their high NOS quality index and the absence of a high 
heterogeneity of the results ensure a certain grade of reliability. Furthermore, data 
about other co-morbidities (like cardio-vascular diseases) were not reported by the 
primary studies, but it’s known that they play an important role in the prognosis also 
of patients with cancer. Moreover, it lacks a comprehensive landscape of the clinical 
data of the patients, since only one study [23] reported this kind of information (tumor 
size, nodal status, tumor grading) by ENE status, limiting general considerations 
about these topics. Therefore, future research should try and disentangle the role of 
co-morbidities on the observed results and should report more complete clinical data. 
Another limitation of this meta-analysis derived from the lack of data from 
multivariate analyses: only two studies [20,23] presented data from multivariate 
models, both significant, but not comparable with a meta-analysis (odds ratios in a 
study [20] vs hazard ratios in the other [23]). Future studies should consider also this 
important point, reporting data on ENE from multivariate analysis. 
Concluding, the present data indicate that ENE in SLN positive breast cancer seems 
to be strongly associated with a poorer prognosis in breast cancer. Its consideration 
becomes thus essential from the gross sampling to the histopathological evaluation 
and the oncologic staging. In spite of the recently developed techniques (e.g. DNA 
sequencing) which allow integrating the pathological report with a complete 
molecular characterization of the tumor in the so called “next-generation 
histopathological analysis” [33,34], all the prognostic roles of the pure morphologic 
features and of the histologic aspects, including ENE, should be clarified. 
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FIGURE CAPTIONS 
 
Figure 1. A classical example of extra-nodal extension of nodal metastasis is here shown. The 
metastatic tumor is a breast carcinoma of non-special type. Note the rupture of nodal capsule and 
the invasion by the metastatic cells of the peri-nodal adipose tissue. (Original magnification: 4x 
lymph node, 10x detail in the box). 
Figure 2. Forrest plots for Relative Risk for Overall Survival (A) and Disease-Free Survival (B) 
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Table 1. Pooled risk ratio estimates for overall and disease free survival according to presence or not of extra-nodal extension.  
 
 
 
  
Abbreviations: ENE: extra-nodal extension. *Events stand for death for overall survival and relapse for disease-free survival. 
 
Parameter N Studies 
N of 
Events* 
in 
ENE+ 
N of 
 ENE+ 
N of 
Events* 
in ENE- 
N of 
ENE- 
Risk Ratio 
(95% CI) 
P-
Value Heterogeneity 
Overall survival 4 34 151 41 423 2.51  (1.66-3.79) <0.0001 Tau² = 0.00; Chi² = 0.45, df =3 (P=0.93); I² = 0% 
Disease free survival 5 36 163 51 461 2.07  (1.38-3.10) <0.0001 Tau² = 0.00; Chi² = 1.87, df = 4 (P =0.76); I² = 0% 
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